With healthcare expenditure in Asia projected to grow by 135 per cent to $2.3 trillion by 2026, the life sciences sector in the region continues to expand rapidly. At its new base at the Biopolis Biomedical Research Hub, Abcam joins over 350 life sciences companies, including eight of the top 10 global pharma players, that have laid down roots in the country. Abcam's new site will service the growing Asia Pacific (APAC) life sciences community, offering scientific and technical support, providing a commercial headquarters for the region. In conversation with BioSpectrum Asia, Rich Lane, Director- Sales and Marketing, APAC region, Abcam talks more about the company's growth plans in the APAC region. Edited excerpts;
What are the major plans in store for the new APAC hub at Singapore?
For a company like Abcam which strongly believes that collaboration is a big driver of progress, it is an exciting opportunity to join one of the world's leading life sciences clusters. We have long standing relationships with key local players (such as A*STAR, Singapore's Agency for Science, Technology and Research) and we are looking to build stronger connections with organisations that share our goal of pushing the boundaries of research.
We recognise that there is a growing mass of world-class academic institutes, biopharma, medtech and other organisations in APAC that need access to the latest innovations and support in order to progress and advance their research. We have established this physical presence at the centre, to be able to better understand their needs and enable us to work together more closely. Singapore is one of the most recognised locations for life sciences in APAC, so it is a great place to base ourselves.
How is the Singapore hub different from the other Abcam's centres in China and Australia?
This story is from the June 2022 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the June 2022 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.
